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Abstract: Rituximab is an important and well established component in the treatment of 
many patients with B-cell non-Hodgkin lymphoma. In this paper we review recent clinical tri-
als investigating the addition of rituximab to standard chemotherapy regimens for treatment of 
patients with diffuse large B cell lymphoma and follicular lymphoma. This report focuses upon 
treatment efficacy, quality of life, and safety of rituximab or rituximab-containing regimens. 
More uniquely, we review economic aspects of lymphoma treatments, including the cost of 
standard chemotherapy regimens with or without rituximab, cost effectiveness of rituximab in 
both induction and maintenance treatment, and lymphoma’s impacts on patient’s productivity 
and their caregivers. We conclude that adding rituximab to standard chemotherapy treatment 
for patients with B-cell non-Hodgkin lymphoma is safe and cost-effective in numerous settings 
during both induction and maintenance therapies. Despite extensive review of the literature, 
many important questions have yet to be answered in the rituximab era and these represent 
important directions for future study.
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Introduction
Rituximab, an anti-CD20 monoclonal chimeric antibody, has significantly improved 
the prognosis of patients with B-cell non-Hodgkin lymphoma (NHL) and changed the 
economics of care delivery for these patients. Diffuse large B-cell lymphoma (DLBCL) 
is the most common histologic subtype of B-cell NHL accounting for approximately 
25% of NHL cases.1,2 In 2005 the incidence rate of DLBCL in the United States 
was approximately 5 cases per 100,000 persons. Incidence varies by ethnicity with 
Caucasian Americans having the highest rates. Incidence increases with age; the median 
age at presentation is 64 years, and like most NHL there is a male predominance (male:
female ratio 1.2:1).3 Follicular lymphoma (FL) is the second most common lymphoma 
in the western world accounting for more than 70% of indolent lymphomas and 22% 
of all NHL.3 It has 3 grades, grade I and II are indolent lymphomas while grade III 
is considered by many experts to be an aggressive lymphoma. It typically occurs in 
middle-aged or elderly adults with the median age at presentation of 60 years and a 
slight female predominance (male to female ratio 1:1.4).3
Rituximab
Rituximab was the first widely adopted monoclonal antibody approved for cancer 
treatment. Rituximab is a monoclonal antibody directed against the CD20 antigen on 
B-lymphocytes. CD20 functions as a calcium channel important in B-cell survival. ClinicoEconomics and Outcomes Research 2010:2 38
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Rituximab’s mechanism of action results from a combination 
of immune-mediated effects and possibly direct induction of 
apoptosis from binding to CD20. When rituximab binds to 
CD20 at the cell surface rituximab activates complement-
dependent cytotoxicity and human Fc receptors, mediating 
cell killing through an antibody-dependent cellular toxicity. 
As has been previously reviewed, the predominant mecha-
nism of rituximab’s anti-lymphoma activity is thought to 
be antibody-dependent cell-mediated cytotoxicity, with a 
lesser role for complement fixation.4 Although rituximab 
has multiple clinical uses, including autoimmune and rheu-
matologic disorders, this review focuses upon rituximab’s 
use in B-cell NHL.
DLBCL treatment
The addition of rituximab concurrently with cytotoxic chemo-
therapy has improved the cure rates for patients with DLBCL 
(Table 1). Prior to the introduction of rituximab, SWOG-8516 
(South Western Oncology Group) a randomized phase III 
trial of CHOP (cyclophosphamide, doxorubicin, vincristine, 
prednisone) vs m-BACOD (low-dose methotrexate with leu-
covorin rescue, bleomycin, doxorubicin, cyclophosphamide, 
vincristine, and dexamethasone) vs proMACE-CytaBOM 
(prednisone, doxorubicin, cyclophosphamide, and etoposide, 
followed by cytarabine, bleomycin, vincristine, and metho-
trexate with leucovorin rescue) vs MACOP-B (methotrexate 
with leucovorin rescue, doxorubicin, cyclophosphamide, 
vincristine, prednisone, and bleomycin) established that 
CHOP remained the standard chemotherapy for patients with 
advanced stage NHL demonstrating intermediate or higher 
grade histologic features.5 Although other regimens induced 
greater toxicities, no regimen showed an improvement in time 
to treatment failure or overall survival compared to the stan-
dard CHOP.5 The addition of rituximab to CHOP resulted in 
an approximately 10% absolute increase in survival beginning 
at one year from initiation of therapy in patients of all ages 
with minimal clinically relevant increases in toxicity.6,7 In the 
MabThera International Trial (MInT), 824 patients younger 
than 60 years with DLBCL (28% stage III/IV and 48% 
with bulky disease) were randomly assigned to treatment 
with 6 cycles of CHOP-like chemotherapy with or without 
rituximab.8 Bulky and extra-nodal sites received additional 
radiotherapy. After a median follow-up of 34 months, patients 
assigned to Rituximab-CHOP (R-CHOP) had significantly 
higher rates of 3-year event-free (79% vs 59%; P  0.001) and 
overall (93% vs 84%; P  0.0001) survival. In 3 randomized 
prospective studies consisting of approximately 2000 older 
patients (65 years of age) with advanced DLBCL, therapy 
with R-CHOP resulted in significantly higher overall survival 
at 3 (approximately 70% vs 57% for CHOP alone), 5 (58% vs 
45%), and 7 years.9–13
Following these reports that the addition of rituximab 
to CHOP improved response rates and overall survival, 
further studies were conducted to investigate the impact of 
maintenance rituximab after initial chemotherapy. Patients 
who received CHOP chemotherapy for induction treatment 
have an initially improved survival when administered 
maintenance rituximab following CHOP chemotherapy com-
pared to patients who received CHOP chemotherapy only.11 
However, survival benefit disappeared with longer follow-up 
suggesting that unlike induction combination chemotherapy 
with rituximab, rituximab maintenance may delay clinically 
evident progression but does not increase the cure rate.14 
Additionally, maintenance therapy with rituximab provided 
no significant benefit in those who received initial therapy 
with R-CHOP for DLBCL.14
Although the addition of rituximab to CHOP has 
improved the cure rates for patients with DLBCL, 
Table 1 Treatment of diffuse large B-cell lymphoma
Trial  Treatment  Follow-up  
period
Results  Schema  P value 
MinT8
N = 824
CHOP
R-CHOP
34 months EFS: 59% OS: 79%
EFS: 84% OS: 93%
1st line EFS P  0.001
OS P  0.0001
Habermann11
N = 415
CHOP
R-CHOP
3 years FFS: 46%
FFS: 53%
1st line P = 0.04
Coiffier13
N = 399
CHOP
R-CHOP
7 years EFS: 25% OS: 36%
EFS: 42% OS: 53%
1st line EFS P  0.0001 
OS P = 0.0004
Kewalramani15
N = 36
iCE
R-iCE
2 years
 
CRR: 27% PFS: 43%
CRR: 53% PFS: 54%
2nd line
 
PFS P = 0.25
CRR P = 0.01
Abbreviations: EFS, event-free survival; OS, overall survival; FFS, failure-free survival; CRR, complete response rate; PFS, progression-free survival.ClinicoEconomics and Outcomes Research 2010:2 39
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a significant portion of patients still have recurrence and 
require additional therapies. Rituximab may play an impor-
tant role in addition to standard chemotherapies in this 
setting as well. Thirty-six patients with relapsed or refrac-
tory DLBCL were treated with rituximab plus ifosfamide, 
carboplatin, and etoposide (R-ICE).15 The complete response 
rate was 53%, significantly better than the historical control 
rate of 27% achieved for DLBCL treated with ICE alone 
(P = 0.01). Progression-free survival rates of patients who 
underwent transplantation after R-ICE trended toward 
improvement compared to historical controls who underwent 
transplantation after ICE (54% vs 43% at 2 years) but weren’t 
statistically significant in this analysis (P = 0.25). The ICE 
and R-ICE regimens have been very effective cytoreduction 
and stem cell mobilization regimens, and reasonable options 
for patients eligible for subsequent hematopoietic stem cell 
transplant (HSCT).15,16
Hematopoietic stem cell transplantation (HSCT) is a clini-
cally necessary treatment for many patients with DLBCL and 
significantly impacts the economics of these patients’ care. In 
the United States, autologous HSCT is considered standard-
of-care for many patients who achieve a second remission 
from DLBCL following a first recurrence. HSCT during the 
first remission is associated with significant morbidity and 
survival is similar in patients administered chemotherapy 
with or without HSCT.17 An intergroup trial (S9704) enrolled 
patients with high intermediate and high risk international 
prognostic index (IPI) scores according to age-adjusted index 
and randomized treatment to 6 cycles of R-CHOP followed 
by autologous HSCT vs 8 cycles of R-CHOP alone. We await 
results of this United States intergroup trial before recom-
mending HSCT for this subgroup of patients.
Including rituximab with HSCT may improve the 
clinical results achieved with HSCT chemotherapy alone. 
A Phase III randomized trial (CORAL) comparing two 
rituximab-based regimens both followed by HSCT and 
maintenance rituximab or not in relapsed or refractory 
DLBCL found that rates of 2-year event-free survival were 
significantly reduced in a subset of patients with prior expo-
sure to rituximab when compared with patients who were 
rituximab-naïve.18,19 In one modest-sized study, rituximab 
was given to 35 patients with recurrent or refractory aggres-
sive NHL (25 with DLBCL) following high-dose therapy 
and autologous HSCT.20 Rituximab was given for 4 weeks 
starting at day 42 post-HSCT in all patients, and again at 6 
months post-HSCT in 31 patients. At a median follow-up of 
30 months, the estimated 2-year event-free and overall sur-
vivals were 81% and 85%, respectively, for the 21 patients 
with relapsed or refractory DLBCL. Although delayed and 
severe neutropenia, including some patients with an absolute 
neutrophil count less than 500/mm3, as well as profound 
B-cell inhibition were observed, the treatment program 
was well-tolerated. In a second trial, high-dose rituximab, 
1000 mg/m2 rather than standard-dose 375 mg/m2, was 
administered during stem cell mobilization, BEAM (car-
mustine, etoposide, cytarabine, melphalan) chemotherapy, 
and on days 1 and 8 after HSCT in 67 patients.21 At a median 
follow-up of 20 months, estimated 2-year disease-free and 
overall survival (OS) were 67% and 80%, respectively 
(P = 0.002), significantly better than those of a historical 
control group receiving the same preparative regimen with-
out rituximab 43% and 53%, respectively (P = 0.004).
FL treatment
Unlike DLBCL, no consensus exists for a standard-of-care 
initial treatment for patients with newly diagnosed FL. 
Indeed, the decision to begin treatment as opposed to con-
tinued observation is often a subjective decision. In the 
United States, significant regional variations exist in the 
care of patients with FL. For example, initial observation 
without treatment was recommended for 29% of patients in 
the northeast but only 13.3% of patients in the southeast.22 
Cyclophosphamide, doxorubicin, and fludarabine based 
regimens may all be considered for first and subsequent 
treatments (Table 2).
The most commonly prescribed initial treatment for FL 
is R-CHOP, the same regimen that is considered standard-of-
care for DLBCL.22 The initial trial of R-CHOP for patients 
with de novo and recurrent FL reported a 95% response 
rate and 55% complete response rate.23 Subsequently, 
a randomized trial of CHOP vs R-CHOP for initial treatment 
of patients with FL reported a 90% response rate and 17% 
complete response rate for CHOP vs 96% and 20% respec-
tively for R-CHOP (P = 0.011).24 For patients who do not 
receive CHOP for initial therapy, CHOP is often considered 
for second line therapy. As a second-line treatment, R-CHOP 
therapy has a significantly higher complete response rate 
than CHOP therapy alone, 30% vs 16% (P  0.0001), which 
translated into a significantly prolonged median progres-
sion-free survival (PFS) from first randomization, 33.1 vs 
20.2 months (P = 0.0003).25
Another common FL treatment regimen, cyclophos-
phamide, vincristine, and prednisone (CVP) is significantly 
improved with the addition of rituximab.26 Adding rituximab 
to CVP (R-CVP) in previously untreated patients with 
stage III/IV FL improves complete response rates from ClinicoEconomics and Outcomes Research 2010:2 40
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57% to 81% and improves overall survival after 53 months 
median follow up from 77% to 83% without increasing seri-
ous adverse events (P  0.0001).
Regimens containing fludarabine, a nucleoside analogue, 
have shown high response rates and are another consider-
able regimen for initial and subsequent therapy for patients 
with FL. Patients receiving R-FCM (rituximab, fludarabine, 
cyclophosphamide, mitoxantrone) as induction therapy will 
achieve significantly higher complete response (CR) and 
overall response rates (ORR) than those who receive induc-
tion with FCM alone.27 In a trial that combined patients 
with relapsed FL and mantle cell lymphoma and random-
ized patients to receive FCM with or without rituximab, the 
R-FCM arm was significantly superior in ORR, PFS and OS. 
In the FL subgroup, the patients receiving the rituximab-
containing induction arm had a 94% ORR vs 70% in FCM 
alone arm (P = 0.011); PFS was also significantly longer in 
the R-FCM arm (P = 0.0139).
More recently, bendamustine and rituximab (BR) com-
binations have been studied in patients requiring initial 
treatment of FL and in patients with relapsed disease. In 
the frontline setting, BR has a similar overall and complete 
response rate 94% and 41% compared to R-CHOP 93% and 
33%.28 The R-CHOP arm also had more hematologic and 
infectious toxicities than the BR arm.28 For patients with 
relapsed FL, BR has reported a 92% response rate with 41% 
complete response in a study of 67 patients.29 Increasingly, 
BR is reasonable treatment option for initial or subsequent 
treatment for patients with FL.
Radioimmunotherapy, linkage of monoclonal antibody to 
radioisotope for intravenous administration, is another treat-
ment option for patients with FL. In patients with advanced 
stage FL receiving I131-tositumomab as initial therapy, 95% 
responded and 75% had a complete response.30 Radioim-
munotherapy has also been investigated as a consolidation 
therapy after cytotoxic chemotherapy. An international, ran-
domized, phase III trial evaluated the efficacy and safety of 
consolidation with Yttrium90 ibritumomab tiuxetan in patients 
with advanced-stage FL in first remission. Consolidation 
with Y90-ibritumomab tiuxetan is highly effective with no 
unexpected toxicities, prolonging PFS by 2 years and result-
ing in high partial response (PR) conversion to CR rates with 
multiple first-line induction combinations.31
Maintenance treatments with rituximab after patients 
are in remission from FL are effective at delaying time 
until recurrence in some instances for patients with FL. 
Two phase II trials of rituximab maintenance after ritux-
imab monotherapy induction suggested that rituximab as a 
first-line treatment with scheduled maintenance at 6-month 
intervals produces high overall and complete response 
rates and a longer PFS , 34 months, than has been reported 
with a typical 4-week treatment alone.32,33 The Phase III 
Swiss Group for Clinical Cancer Research (SAKK) 35/98 
trial enrolled both newly diagnosed and previously treated 
Table 2 Treatment of follicular lymphoma
Trial Treatment Results Schema P value
Hiddemann24
N = 428
CHOP
R-CHOP
RR: 90% CR: 17%
RR: 96% CR: 20%
1st line P = 0.011
van Oers25
N = 465
CHOP
R-CHOP
ORR: 72% CR: 16%
ORR: 85% CR: 30%
2nd line P  0.001
RM
OBS
PFS: 52 mo OS: 85%
PFS: 15 mo OS: 77%
2nd line PFS P  0.001
OS P = 0.011
Marcus26
N = 321
CvP
RCvP
CRR: 57% OS: 77%
CRR: 81% OS: 83%
1st line CRR P  0.0001
OS P = 0.029
Forstpointner27
N = 65
FCM
R-FCM
ORR: 70% CR: 23%
ORR: 94% CR: 40%
1st line ORR P = 0.011
Rummel28
N = 437a
R-CHOP
BR
ORR: 93% CR: 33%
ORR: 94% CR: 41%
1st line Not reported
Robinson29
N = 67b
BR
 
ORR: 92% CR: 41%
 
2nd line
 
Ci 95%
 
a52% of the patients had follicular lymphoma, 20% had mantle cell lymphoma and 28% had other lymphoma.
bpatients had indolent non-Hodgkin lymphoma and mantle cell lymphoma.
Abbreviations: CI, confidence interval; RM, rituximab maintenance; OBS, observation; BR, bendamustine with rituximab; mo, month; RR, response rate; CR, complete response; 
ORR, overall response rate; PFS, progression-free survival; OS, overall survival.ClinicoEconomics and Outcomes Research 2010:2 41
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patients with FL. Overall, 151 patients (51 of whom were 
previously untreated) achieved CR, PR, or stable disease 
after rituximab monotherapy induction (four once weekly 
doses) and were subsequently randomized to either no fur-
ther treatment or rituximab maintenance therapy consisting 
of four single rituximab infusions administered at 2-month 
intervals. In the initial publication, with a median follow-up 
of 35 months, median event-free survival among all patients 
receiving maintenance therapy was significantly longer than 
that achieved by patients receiving no further treatment, 23 vs 
12 months (P = 0.024).34 With 8 years of follow-up, no long-
term toxicities were attributable to maintenance rituximab 
and 20% of patients still remained in remission.35 Overall 
this study showed that rituximab maintenance after rituximab 
monotherapy induction significantly improves outcomes in 
FL in terms of both response duration and event free survival, 
without causing additional toxicity. Recently, a comprehen-
sive review and meta-analysis concluded that maintenance 
therapy with rituximab, either as 4-weekly infusions every 
6 months or as a single infusion every 2 to 3 months, should 
be added to standard therapy for patients with relapsed or 
refractory FL after successful induction therapy.36
Rituximab maintenance after initial chemotherapy induc-
tion is significantly better than induction chemotherapy alone. 
A Phase III trial conducted by the Eastern Co-operative 
Oncology Group (ECOG 1496) studied 305 evaluable 
patients with newly diagnosed advanced stage indolent 
NHL.37 Most of these patients, 78%, had advanced stage FL. 
Those patients achieving a complete or partial response 
or stable disease following CVP induction chemotherapy 
were randomized to either rituximab maintenance therapy 
or standard observation. The rituximab maintenance was 
dosed weekly for 4 doses and repeated at 6-month intervals 
for up to 2 years. Analyses conducted in the FL subgroup 
revealed 3-year PFS after random assignment was 64% for 
the maintenance group vs 33% for the observation group 
(hazard ratio [HR] = 0.4; P  0.001). Among patients with 
FL, OS at 3 years was 91% for the maintenance group vs 86% 
for the observation group (HR = 0.6; P = 0.08). This study 
provides strong evidence that rituximab maintenance has a 
significant survival benefit for patients with FL who receive 
induction chemotherapy without the inclusion of rituximab 
during induction.
Similar, but more compelling, conclusions have been 
drawn in the relapsed setting. In European Organization for 
the Research and Treatment of Cancer (EORTC) protocol 
20891, patients were randomized to CHOP or R-CHOP 
induction therapy for a first recurrence of FL. After six cycles 
of induction chemotherapy; patients who achieved complete 
or partial responses underwent another randomization to 
rituximab maintenance or standard observation. Ritux-
imab maintenance significantly prolonged the PFS from 
14.9 months in the observation to 51.5 months (P  0.0001); 
rituximab maintenance also improved OS at 3 years from 
77% with observation alone to 85%.25 In a subgroup analysis 
of patients who received CHOP for induction, rituximab 
maintenance resulted in a median PFS from second random-
ization of 42.2 months vs 11.6 months in the observation 
arm (HR, 0.30; P  0.001). For patients receiving R-CHOP 
induction, rituximab maintenance resulted in a median PFS 
from second randomization 51.8 months vs 23.0 months in 
the observation arm (HR, 0.54; P = 0.004). As a conclusion 
from this study; rituximab maintenance was still beneficial 
after R-CHOP induction but a survival benefit was clearer 
in patients who only received CHOP induction.
Maintenance rituximab after autologous HSCT is another 
interesting treatment consideration. The efficacy and safety 
of rituximab maintenance therapy administered once monthly 
after autologous HSCT were retrospectively analyzed in 
27 patients with NHL treated at a single institution.38 Of these 
27 patients, 12 had FL and were in CR at the time of trans-
plantation. After a median follow-up period of 30 months, 
all 12 patients were still alive and, except for 1 patient who 
transformed from indolent to aggressive disease, there were 
no relapses. Another study incorporated in vivo purging 
with rituximab around the time of stem cell pheresis with 
maintenance rituximab after autologous HSCT. Twenty-three 
patients with relapsed FL were enrolled in this prospective 
single-arm study.39 Five-year OS and 5-year PFS are 78% 
(95% confidence interval [CI] 61% to 95%) and 59% (95% 
CI 38% to 80%), respectively. Time to progression with the 
rituximab-containing regimen was significantly improved 
compared with each patient’s previous treatment (P  0.001). 
Durable molecular remissions, documented by quantita-
tive polymerase chain reaction testing, occurred in 11 of 
13 patients. Despite the prolonged hypogammaglobulinemia, 
no increase in major infections was observed.
Cost of lymphomas
The loss of life-years from DLBCL is hard to estimate and 
we found no previous reports in our review of the literature. 
A retrospective analysis of 374 patients with newly diag-
nosed stage II–IV aggressive NHL treated between 1993 
and 2001 in The Netherlands with CHOP chemotherapy 
showed the mean first-line treatment costs (excluding G-CSF) 
were €10,047 ($10,254) for patients younger than 60 years ClinicoEconomics and Outcomes Research 2010:2 42
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of age and €12,232 ($12,484) for patients older than 60.40 
Two-year follow-up costs averaged €14,039 ($14,328) and 
€9,026 ($9,211) for the two age groups, respectively. A large 
retrospective analysis of direct medical costs for the entire 
pathway of care for DLBCL was conducted between 1998 
and 2004 in Canada.41 Patient samples were defined as those 
who received R-CHOP (n = 85) or CHOP (n = 86) as first-line 
treatment. CHOP cost was CAN$12,240 ($8,800) and the 
1-year follow up cost was CAN$8,929 ($6,400) compared to 
R-CHOP cost of CAN$33,088 ($22,680) with 1-year follow 
up costs of CAN$3,215 ($2,311). In European healthcare 
systems between 2000 and 2003, the mean cumulative cost 
of CHOP was $3,358 and R-CHOP was $17,225.42 The post-
treatment cancer surveillance cost for CHOP was $3,950 
compared with $5,202 for R-CHOP.
Often thought of as one of the most costly treatments, 
HSCT adds significant expense to the care of patients who 
require this modality of care. For patients with refractory or 
relapsed NHL, the cost from induction chemotherapy until 
3 months after discharge from inpatient care following the 
transplant was €15,000 ($15,300) from 1994 to 1998 in 
The Netherlands.43 Similarly, the cost for autologous HSCT 
for the Canadian system in 1993/1994 was CAN$ 22,089 
($16,029).44
The loss of life-years is harder to estimate from FL 
because patients may undergo multiple series of treatments 
over a decade or more after diagnoses. Although the attempts 
to capture the costs of chemotherapy for FL have not always 
accounted for infusion related and follow up costs, in 2007 
the cost of 8 cycles of CVP in the US was $500, 6 cycles 
R-CVP $24,500, and CHOP as salvage over 6 months costs 
$3,829.45 Further, autologous HSCT for treatment of FL in 
the US in 2007 was estimated to cost $75,352.45 Although 
this cost is much higher than reviewed for DLBCL, this dif-
ference is likely related to healthcare inflation and differences 
in cost between healthcare systems and not due to differences 
between the diseases. As with DLBCL, the cost to patients 
and families for lost productivity is likely significant, but has 
not been well measured.
Despite the extensive publications about NHL treatments, 
little is known about how treatment impacts on patients’ work 
and daily activities. A cross-sectional study of work produc-
tivity, activity impairment, and impacts on caregivers was 
conducted with 84 patients with NHL. Of the 71% of patients 
who worked before diagnosis; only 41% continue to work 
after treatment with 36% transitioning to retirement, sick 
leave (10%) and unemployment (4%).46 Active chemotherapy 
treatment was associated with significant activity impairment 
(OR 14.5; 95% CI 0.91 to 230.9; P = 0.059). A significant 
proportion of patients required caregiver assistance (23%); 
with 33% of their working days being missed as a conse-
quence of this care.46 Those caregivers suffered from physical, 
psychological, and financial disruptions. Another large cohort 
study reported that 13% of all survivors had stopped working 
for cancer-related reasons within 4 years of diagnosis. More 
than 50% of all survivors had stopped working after the first 
year with 75% of those who stopped working returning to 
work in the future when they are off treatment.47 Survivors 
of stage IV blood and lymph malignancies have one of the 
highest adjusted risk of disability or quitting work amongst 
all patients with cancer.47
Given the high costs of these illnesses and their treat-
ments; much work has gone into determining the most 
cost-effective approaches for care delivery (Table 3). 
A cost-effectiveness analysis of CHOP vs R-CHOP for ini-
tial treatment of patients with DLBCL has been presented 
from a European payer perspective.48 Chemotherapy cost 
was estimated from a phase III trial in France, Belgium, 
and Switzerland. The survival and cost-effectiveness was 
estimated from 4 years to 15 years. R-CHOP resulted in 
20.6% relative increase in complete response rate, absolute 
increase from 63% to 76%, and a 31% decrease in risk of 
death at four years. Over 15 years mean, median OS was 
estimated to be 6.9 years for R-CHOP and 5.74 years for 
CHOP, a mean increase in OS of 1.16 years (or 1.07 qual-
ity adjusted life year [QALY]s). Total direct medical costs 
were €13,170 ($11,250) higher with R-CHOP, with an 
incremental cost-effectiveness ratio of €12,259 ($10,477) per 
QALY gained which looks favorable comparing to standard 
worldwide accepted ranges. Similarly, the incremental cost 
effectiveness of CHOP vs R-CHOP in DLBCL patients in 
Netherlands has been reported.49 A transition state model was 
developed to estimate the clinical course, costs and quality 
Table 3 Cost of diffuse large B-cell lymphoma treatment
Study 
 
 
Treatment 
 
 
Follow-up  
period 
 
Cost 
1st line  
cost
Follow-up   
cost
Hornberger42
N = 399
CHOP
R-CHOP
5 years $3,358
$17,225
$3,950
$5,202
van Agthoven43
N = 374
CHOP 2 years $10,254–
$12,232
$9,211–
$14,328
Lee41
N = 171
CHOP
R-CHOP
1 year
 
$8,800
$22,680
$6,400
$2,311ClinicoEconomics and Outcomes Research 2010:2 43
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of life (QOL) differences between the two groups. The only 
costs included were direct medical costs. The time horizon 
of the model was 15 years. The incremental gain was 0.88 
QALYs favoring the addition of rituximab to CHOP. The 
costs were €12,343 ($10,550) higher in the younger group of 
patients and €15,860 ($13,555) in the older patients.49 This 
resulted in an incremental cost-effectiveness ratio (ICER) of 
€13,983 ($11,950) for the younger and €17,933 ($15,327) for 
the older patients per QALY gained.49 An additional study 
compared the direct medical cost of CHOP and R-CHOP in 
young patients with favorable IPI risk DLBCL from the per-
spective of the Italian National Health Service.50 The model 
provided an estimate of mean survival and mean costs over a 
3-year period. The QALYs gained with R-CHOP was greater 
than with CHOP. In the R-CHOP regimen, the additional 
costs of rituximab €10,086 ($14,780) were balanced by the 
lower additional therapy costs €10,803 ($15830) leading to a 
lower overall mean treatment cost per patient with R-CHOP 
regimen than with the CHOP regimen €22,113 ($32,400) vs 
€22,831 ($33,460).
In FL, the cost effectiveness of adding rituximab to CVP 
has been reported45 and the mean overall survival is projected 
to be 1.51 years longer for patients receiving R-CVP than 
CVP. The cost per QALY gained is $28,565 and the ICER 
of R-CVP compared with CVP is projected to be accept-
able under a range of sensitivity analyses in the United 
States. The cost-effectiveness of maintenance rituximab 
for US patients with FL in second remission has also been 
reported.51 Five years after R-CHOP and achieving a second 
remission, disease-free survival is expected to be 47% and 
22%, and the OS rates are estimated to be 73% and 61% for 
extended adjuvant rituximab and observation, respectively. 
The discounted ICER for the addition of adjuvant rituximab 
is estimated to be $19,522 per QALYs gained. The authors 
concluded that maintenance rituximab offers a clinical benefit 
to patients who have a second remission from FL at a cost 
generally acceptable to the US healthcare system. Similarly, 
a cost-effectiveness analysis of maintenance rituximab during 
second remission for patients in Sweden was conducted and 
concluded to be a reasonable value for patients who achieve 
a complete response to induction chemotherapy.52
Patient focused outcomes
The addition of rituximab to CHOP chemotherapy may not 
add significantly to the symptoms or toxicities of CHOP 
chemotherapy alone. QOL was evaluated during a prospec-
tive randomized trial of rituximab maintenance therapy 
in 91 NHL patients (38 with DLBCL and 16 with FL).53 
QOL was assessed with the standardized questionnaires 
EORTC-QLQ-C30, EuroQol-5D, and EuroQol-5D (VAS). 
No differences in QOL were found between the groups 
that received rituximab maintenance or standard observa-
tion. We are not aware of any reports that have specifically 
ascertained patient satisfaction with receiving rituximab 
during treatment for DLBCL or adherence with treatment 
recommendations. Similarly, uptake of R-CHOP in place of 
CHOP seems nearly universal when health care systems are 
able to offer rituximab, although objective data to support 
this belief are lacking.
In FL, the addition of rituximab to CHOP did not clini-
cally significantly increase the toxicity of induction therapy.25 
In SAKK 35/98, maintenance rituximab was well tolerated. Of 
the 137 patients who were evaluable for toxicity, only 7% in both 
the maintenance and observation arms reported toxicities.34 In 
Eastern Cooperative Oncology Group (ECOG) protocol 1496, 
rituximab maintenance or observation after induction therapy 
with CVP, rituximab maintenance was well tolerated and did 
not lead to significantly higher rates of neutropenia, thrombo-
cytopenia, or infection compared with observation alone.37 In 
EORTC 20891, rituximab maintenance vs observation after 
induction therapy with either CHOP or R-CHOP, rituximab 
maintenance treatment was associated with minimal toxicity.25 
Only 6 out of 167 patients (4%) had to discontinue treatment 
because of toxicity. Four of the six patients were discontinued 
due to infections, and there was no treatment-related mortality. 
As in DLBCL, patient satisfaction, acceptability, physician 
uptake, and adherence have been widely reported and our 
literature review failed to return any relevant reports.
Future directions
Although there are many investigations of rituximab in NHL 
many questions still await an answer. Despite the fact that 
all studied maintenance schedules have been shown to be 
effective in FL; we are still unsure about the optimal dos-
ing, schedule, and duration of this maintenance. Because all 
of the rituximab maintenance studies have been conducted 
over the last 7 years, there is no clear guidance yet about 
long term safety and efficacy. Questions remain about the 
risks of decreased immunoglobulin levels and infection rates, 
activating cutaneous squamous cell carcinoma, and selection 
for CD20 negative lymphoma relapses. Questions about the 
long-term safety require longer follow up. The impact of 
rituximab maintenance on patient’s QOL and productiv-
ity and caregiver burden should be studied further. Some 
researchers and advocates have suggested that receiving 
maintenance treatments may reduce QOL due to treatment ClinicoEconomics and Outcomes Research 2010:2 44
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burden but others have advocated that maintenance may 
increase patient’s feeling of satisfaction as they participate 
in actively managing their disease. Further research is clearly 
indicated. Despite our careful review, we are not aware of 
data to assess patients’ acceptance or physicians’ uptake of 
rituximab. Although treatment with rituximab is clinically 
beneficial in several patient settings, future investigations 
may allow doctors and patients to optimize the treatment 
effect and refine approaches that improve patient-focused 
outcomes and limit economic burden.
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